- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07704476
EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer
In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Clinical Trials Contact
- Numero di telefono: 412-330-6151
- Email: ctgov@ahn.org
Luoghi di studio
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Reclutamento
- AHN Allegheny General Hospital
-
Contatto:
- Clinical Trials Contact
- Numero di telefono: 4123306151
- Email: ctgov@ahn.org
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Non ancora reclutamento
- AHN Allegheny General Hospital
-
Contatto:
- Clinical Trials Contact
- Numero di telefono: 412-330-6151
- Email: ctgov@ahn.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance by a CSCS
- Must be able to read and understand English and consent for themselves.
Exclusion Criteria:
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Beta blocker or GLP-1 inhibitor medications
- Pregnant women
- Males
- Lactose intolerance
- Cow's milk or whey protein allergy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: 60 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle). |
60 grams of whey protein |
|
Sperimentale: 0 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle). |
0 grams of whey protein |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Determine changes in pounds of muscle and fat mass after each exercise regimen
Lasso di tempo: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Determine changes in resting metabolic rate in calories per day at the completion of the exercise regimen
Lasso di tempo: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in body composition at the completion of the exercise regimen, including body mass in pounds, fat mass in pounds, fat-free mass in pounds, % fat, and % fat-free mass
Lasso di tempo: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in Y-balance score at the completion of the exercise regimen
Lasso di tempo: Baseline and at program completion (within 4 weeks of exercise completion)
|
Y-Balance score measures the length an individual can extend their foot. The larger the score the better the balance. |
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Functional Movement Screen (FMS) scores at the completion of the exercise regimen
Lasso di tempo: Baseline and at program completion (within 4 weeks of exercise completion)
|
FMS measures movement patterns with scoring from 0 to 21. The large the score the better the mobility. |
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Determine changes in phase angle at the completion of the exercise regimen
Lasso di tempo: At program completion (at 8 weeks)
|
Phase angle measures the fluidity of cells and the larger the value the better. |
At program completion (at 8 weeks)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Colin Champ, MD, CSCS, AHN Radiation Oncology
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Malattie della pelle
- Malattie del seno
- Comportamento
- Malattie della pelle e del tessuto connettivo
- Neoplasie
- Neoplasie mammarie
- Attività motoria
- Aminoacidi, peptidi e proteine
- Proteine
- Cibo
- Dieta, cibo e nutrizione
- Fenomeni fisiologici
- Cibo e bevande
- Prodotti lattiero -caseari
- Latte
- Proteine dietetiche
- Proteine del latte
- Proteine animali, dieta
- Siero
- Proteine del siero di latte
Altri numeri di identificazione dello studio
- 2026-159-SG
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .